

## **Minutes: Steering Board meeting, 4 December 2020**

### **1. Update on the Moderna contract**

The Members were informed that the contract was submitted to Moderna and to Commissioner Kyriakides for signature. Next steps were also indicated.

### **2. Update on the allocation of doses** [REDACTED]

The [REDACTED] for **Moderna** was open and Members provided feedback on the **base volume** but also, in parallel, expressed preferences as regards [REDACTED]

A revised version of the table with a new indicative **column on donation** would be circulated, while the feasibility and conditions for donation would be further discussed, including in a dedicated subgroup.

**Pfizer/BioNTech** – the members were informed that the Commission received Word version of **Order forms** and invited them to submit the forms as soon as possible.

The Commission informed that Pfizer was trying to accommodate the **batch size** with the demands from the MSs, consequently it was possible that some MSs would receive [REDACTED] for which the consent of the MSs would be required. This would not affect the first deliveries [REDACTED].

Some MSs requested a more [REDACTED] of the vaccines volume [REDACTED]

The Members were reassured that the submission of the corrected Order Forms would not delay the schedule for delivery as Pfizer considered they had received the Order Form on [REDACTED]

### **3. Update on contracts in the [REDACTED] and discussions with other companies**

**Novavax** - a meeting was organised to clarify the last pending key issues [REDACTED] [REDACTED]. The Commission announced the end of the exploratory talks and the intention to go into the [REDACTED]. The Members were informed on key elements of the envisaged contract (price, upfront payment, delivery schedule etc.).

**Valneva** – exploratory talks were over. The Members were informed on key elements of the envisaged contract (price, volume, upfront payment etc).

The Members were in favour of launching the contract [REDACTED], [REDACTED] [REDACTED]. It was outlined that Valneva proposed a different technology and Members agreed it would be useful to have it in the portfolio.

[REDACTED] - discussions with the company were over and the Steering Committee should decided.

[REDACTED] exploratory talks continued.

It was suggested that a strategic discussion should take place on how to handle future vaccine candidates.

#### 4. Discussion on national vaccination strategies and logistics

Member States exchanged on the **starting point** and **schedule** of the national vaccination strategies.

The Commission and the Members agreed on the importance of **unity** amongst the Member States and a **coordinated approach** regarding the implementation of the vaccines strategies.

The importance of **waiting for the formal EMA evaluation** and the **(conditional) marketing authorisation** was also underlined.

The Commission provided an update on the state of play on the **Joint Procurement for needles and syringes**.

#### 5. COVAX

The Commission provided an update on the state of play on the **COVAX APAs**.

[REDACTED]  
[REDACTED].

Regarding **donations**, the importance of an early delivery was outlined.

The Members were reminded that a **subgroup on vaccine donation**, reporting to the Steering Board, would be set up with a 1<sup>st</sup> meeting on Thursday, 10 December. Member States were invited to nominate representatives in this subgroup.

The Commission also underlined that the Council Conclusions of the next EUCO would probably contain a point on donations.

[Redacted]

[Redacted]  
[Redacted]  
[Redacted]

[Redacted]

- [Redacted]  
[Redacted]
- [Redacted]  
[Redacted]
- [Redacted]
- [Redacted]  
[Redacted]  
[Redacted]  
[Redacted]
- [Redacted]  
[Redacted]  
[Redacted]
- [Redacted]  
[Redacted]

[Redacted]

- [Redacted]
- [Redacted]
- [Redacted]
- [Redacted]
- [Redacted]  
[Redacted]
- [Redacted]  
[Redacted]
- [Redacted]  
[Redacted]
- [Redacted]

[Redacted]